Literature DB >> 9270401

Torsades de pointes with terfenadine ingestion.

R A June1, I Nasr.   

Abstract

Torsades de pointes (TDP) is a ventricular tachycardia that can deteriorate into ventricular fibrillation. TDP has been associated with terfenadine use in cases of liver disease, electrolyte abnormalities, concomitant administration of drugs that inhibit cytochrome P-450, or deliberate overdose. This report describes the first case of TDP in a healthy patient taking the recommended therapeutic dosage of terfenadine.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9270401     DOI： 10.1016/s0735-6757(97)90206-0

Source DB:  PubMed          Journal:  Am J Emerg Med        ISSN： 0735-6757            Impact factor:   2.469


  6 in total

1.  Does terfenadine-induced ventricular tachycardia/fibrillation directly relate to its QT prolongation and Torsades de Pointes?

Authors:  Hua Rong Lu; An N Hermans; David J Gallacher
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

Review 2.  Principles of safety pharmacology.

Authors:  M K Pugsley; S Authier; M J Curtis
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

3.  Non-sedating antihistamines block G-protein-gated inwardly rectifying K+ channels.

Authors:  I-Shan Chen; Chang Liu; Michihiro Tateyama; Izhar Karbat; Motonari Uesugi; Eitan Reuveny; Yoshihiro Kubo
Journal:  Br J Pharmacol       Date:  2019-07-10       Impact factor: 8.739

4.  Validating the Arrhythmogenic Potential of High-, Intermediate-, and Low-Risk Drugs in a Human-Induced Pluripotent Stem Cell-Derived Cardiac Microphysiological System.

Authors:  Verena Charwat; Bérénice Charrez; Brian A Siemons; Henrik Finsberg; Karoline H Jæger; Andrew G Edwards; Nathaniel Huebsch; Samuel Wall; Evan Miller; Aslak Tveito; Kevin E Healy
Journal:  ACS Pharmacol Transl Sci       Date:  2022-07-29

Review 5.  Safety of antihistamines in children.

Authors:  A P Ten Eick; J L Blumer; M D Reed
Journal:  Drug Saf       Date:  2001       Impact factor: 5.228

6.  Ebastine in the light of CONGA recommendations for the development of third-generation antihistamines.

Authors:  S Rico; Rm Antonijoan; Mj Barbanoj
Journal:  J Asthma Allergy       Date:  2009-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.